SynthesisHypertension (Dallas, Tex. : 1979)2024
Optimal Antihypertensive Systolic Blood Pressure: A Systematic Review and Meta-Analysis.
Synthesis in Hypertension (Dallas, Tex. : 1979), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 9 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 9 syntheses or guidelines pooled it.
- Pooled it
- Efficacy and safety of intensive vs. standard blood pressure control: a systematic review and meta-analysis.Frontiers in cardiovascular medicine · 2026Pooled it
- European guidelines for hypertension in 2024: a comparison of key recommendations for clinical practice.Nature reviews. Cardiology · 2025Guideline
- Hypertension Canada guideline for the diagnosis and treatment of hypertension in adults in primary care.Canadian family physician Medecin de famille canadien · 2025Guideline
- Guideline
- Effect of intensive versus standard blood pressure control on cardiovascular outcomes in adult patients with hypertension: a systematic review and meta-analysis.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Pooled it
- Hypertension Canada guideline for the diagnosis and treatment of hypertension in adults in primary care.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2025Guideline
- Systematic Review of the Effectiveness of Intensive Antihypertensive Treatment Goals: Brazilian Society of Cardiology (SBC) Recommendation.Arquivos brasileiros de cardiologia · 2025Pooled it
- Guide de pratique clinique en soins de première ligne d'Hypertension Canada pour le diagnostic et le traitement de l'hypertension artérielle chez les adultes.Canadian family physician Medecin de famille canadienGuideline
- Contemporary achievement of guideline recommendations for blood pressure management after stroke in the CONVINCE trial.European stroke journal · 2026Trial
- Why wait? the case for up-front single-pill combination therapy in stage 1 hypertension.Journal of human hypertension · 2026Review
- Article
- Challenges and Perspectives in Optimising the Treatment of Arterial Hypertension: Role of the Ramipril-Amlodipine-Hydrochlorothiazide Single-Pill Combination.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2026Review
- Dual-trajectories of Systolic Blood Pressure and Modified Life's Essential 8 With Gastrointestinal Cancer and All-Cause Mortality: A Prospective Cohort Study.Journal of clinical hypertension (Greenwich, Conn.) · 2026Article
- Caribbean and South American team-based strategy to control hypertension (CATCH): Rationale and study design of a cluster randomized trial.American heart journal · 2026Article
- Admission blood pressure and mortality in acute aortic dissection: Southwest China multicenter retrospective cohort study.Scientific reports · 2026Article
- Global trends in hypertension prevalence, awareness, treatment, and control.Current opinion in nephrology and hypertension · 2026Review
- Advancing evidence-based blood pressure targets in JSH2025.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- Evolution in the targets for blood pressure treatment.Current opinion in nephrology and hypertension · 2026Review
- Age-specific associations between blood pressure and cardiovascular disease, kidney disease, and death among individuals with type 2 diabetes: a population-based cohort study.Cardiovascular diabetology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundSystolic blood pressure (SBP) lowering reduces major cardiovascular disease (CVD) and all-cause mortality. However, the optimal target for SBP lowering remains controversial.
methodsWe included trials with random allocation to an SBP <130 mm Hg treatment target and CVD as the primary outcome. Data were extracted from each study independently and in duplicate using a standardized protocol. Random-effects meta-analysis was used to obtain pooled hazard ratios (HRs) and 95% CIs for CVD and all-cause mortality comparing SBP <130 and ≥130 mm Hg treatment targets. A secondary analysis compared the same outcomes for randomization to an SBP target of <120 or <140 mm Hg.
resultsSeven trials, including 72 138 participants, met the eligibility criteria. Compared with an SBP target of ≥130 mm Hg, an SBP target of <130 mm Hg significantly reduced major CVD (HR, 0.78 [95% CI, 0.70-0.87]) and all-cause mortality (HR, 0.89 [95% CI, 0.79-0.99]). Compared with an SBP target of <140 mm Hg, an intensive SBP target of <120 mm Hg significantly reduced major CVD (HR, 0.82 [95% CI, 0.74-0.91]), but all-cause mortality was marginally insignificant (HR, 0.85 [95% CI, 0.71-1.01]). Adverse events were significantly more likely in the intensive SBP target groups, but the absolute risks were low.
conclusionsThis study suggests targeting an SBP <130 mm Hg significantly reduces the risks of major CVD and all-cause mortality. The findings also support an SBP target of <120 mm Hg, based on a smaller number of trials. REGISTRATION: URL: https://www.crd.york.ac.uk/PROSPERO/; Unique identifier: CRD42023490693.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.